Skip to main content

Table 2 Efficacy endpoints at week 16 using non-responder imputation

From: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Endpoints Secukinumab IV-300 mg (N = 76) Secukinumab IV-150 mg (N = 74) Placebo (N = 76)
ASAS20, n (%) 46 (60.5)§ 43 (58.1) 28 (36.8)
ASAS40, n (%) 32 (42.1) 30 (40.5) 16 (21.1)
hsCRP (post-baseline/baseline ratio), mean change from baseline ± SE 0.48 ± 1.1 0.55 ± 1.1 1.09 ± 1.1
ASAS 5/6, n (%) 30 (39.5) 31 (41.9) 11 (14.5)
BASDAI, mean change from baseline ± SE -2.7 ± 0.3 -2.3 ± 0.3 -1.5 ± 0.3
ASAS partial remission, n (%) 16 (21.1) 7 (9.5) 1 (1.3)
  1. Non-responder imputation (binary variables) and mixed-model repeated measures (continuous variables) data are presented
  2. ASAS20 20% response according to criteria of the Assessment of Spondyloarthritis International Society, ASAS40 40% response according to ASAS criteria, hsCRP high-sensitivity C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index
  3. ASAS Assessment of SpondyloArthritis international Society, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, N number of patients, SE standard error
  4. P < 0.05, § P < 0.01 vs placebo. P values were adjusted for multiplicity of testing